Navigation Links
Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010

MOUNTAIN VIEW, Calif., July 20 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for its fiscal quarter ended June 30, 2010, on Monday, July 26, 2010 following the close of the U.S. financial markets.  The Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results, on Monday, July 26 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at  A replay of the call will be available for two weeks following the event.  

To access the live conference call via phone, dial 888-713-4216.  International callers may access the live call by dialing 617-213-4868.  The reference number to enter the call is 72715175.

The replay of the conference call may be accessed via the Internet, at, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers.  The reference number for the replay of the call is 91278191.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.  For more information about Alexza, the Staccato technology or the Company's development programs, please visit

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
2. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
3. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
4. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
5. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
6. Alexza Pharmaceuticals Files Shelf Registration Statement
7. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
8. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
9. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
10. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
11. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
Post Your Comments:
(Date:12/1/2015)... A federal court has denied the state of ... filed by the Pharmaceutical Care Management Association (PCMA) challenging the ... law that forces employers and consumers to pay drugstores higher ... must now defend a law that raises health care ... Mark Merritt . --> Arkansas ...
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from ... care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... payments per claim with more than seven days of lost time continued to be ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... vast improvements in scientific research and discoveries, leading us to better understand the ... relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... It’s official: ... a tattoo — a number even greater among Millennials (a whopping one in three ... more and more people who are dissatisfied with their ink. In fact, RealSelf ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many ... the film for accurate interpretation by the radiologist. The marking utensils are so ... Sacramento, Calif., has found a way to alleviate this problem. , He developed ...
Breaking Medicine News(10 mins):